US2021113514A1PendingUtilityA1
Aminocarbonylcarbamate compounds
Assignee: SK BIOPHARMACEUTICALS CO LTDPriority: Feb 28, 2014Filed: Dec 29, 2020Published: Apr 22, 2021
Est. expiryFeb 28, 2034(~7.6 yrs left)· nominal 20-yr term from priority
Inventors:Young Soon KangJin Yong ChungCheol Young MaengHan Ju YiKi-Ho LeeJoon HeoEun-Hee ChaeYu Jin Shin
C07C 275/60A61K 9/0053A61P 25/00A61K 31/325A61K 31/27A61K 45/06A61P 25/26
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R 1 and R 2 are independently H— or alkyl; R 3 is H—, alkyl or aralkyl; and R 4 is H— or aryl.
Claims
exact text as granted — not AI-modified1 .- 15 . (canceled)
16 . A method for treating a dopamine reuptake-related disease comprising:
administering to a mammal in need thereof an oral or parenteral formulation comprising (a) a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof and (b) a therapeutically effective amount of an agent selected from the group consisting of adderall, concerta, dexedrine, focalin, metadate, methylin, ritalin, vyvanse, daytrana, and quillivant,
wherein
X is independently halo, alkyl, alkoxy or nitro;
m is 0, 1, 2, 3 or 4
n is 1 or 2;
R 1 and R 2 are independently H— or alkyl;
R 3 is H—, alkyl or aralkyl; and
R 4 is H— or aryl,
wherein at least one of R 1 , R 2 , R 3 and R 4 is not H—,
or a compound selected from the group consisting of:
2-amino-3-(2-chlorophenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-(2,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-(3,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-(4-chlorophenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-(3-chlorophenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-(4-nitrophenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-(4-tert-butylphenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-(2-fluorophenyl)propyl (aminocarbonyl)carbamate;
(2R)-2-amino-3-(2-chlorophenyl)propyl (aminocarbonyl)carbamate;
(2R)-2-amino-3-(2,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
(2R)-2-amino-3-(3,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
2-amino-3-phenylpropyl(aminocarbonyl)carbamate;
(2R)-2-amino-3-phenylpropyl(aminocarbonyl)carbamate; and
a pharmaceutically acceptable salt thereof.
17 . The method of claim 16 , wherein the dopamine reuptake-related disease is selected from the group consisting of fatigue, obesity, narcolepsy, fibromyalgia, cataplexy, drug addiction, sexual dysfunction, restless legs syndrome, bipolar disorder, depression, excessive daytime sleepiness, obsessive-compulsive disorder, and binge eating disorder.
18 . The method of claim 16 , wherein the oral or parenteral formulation further comprises at least one pharmaceutically-acceptable carrier.
19 . The method of claim 18 , wherein the carrier is lactose, dibasic calcium phosphate, corn starch or a mixture thereof.
20 . The method of claim 16 , wherein the compound is a compound of Formula (II):
wherein
X is independently halo, alkyl, alkoxy or nitro;
m is 0, 1, 2, 3 or 4;
n is 1 or 2;
R 1 and R 2 are independently H— or alkyl; and
R 4 is H— or aryl, and
wherein at least one of R 1 , R 2 and R 4 is not H—.
21 . The method according to claim 20 , wherein the compound is selected from the group consisting of:
2-(isopropylamino)-3-phenylpropyl (aminocarbonyl)carbamate; 2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)carbamate; 2-(methylamino)-3-phenylpropyl (aminocarbonyl)carbamate; and 2-amino-3-phenylpropyl (anilinocarbonyl)carbamate.
22 . The method according to claim 21 , wherein the compound is selected from the group consisting of:
(2R)-2-(isopropylamino)-3-phenylpropyl (aminocarbonyl)carbamate; (2R)-2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)carbamate; (2R)-2-(methylamino)-3-phenylpropyl (aminocarbonyl)carbamate; and (2R)-2-amino-3-phenylpropyl (anilinocarbonyl)carbamate.
23 . The method according to claim 22 , wherein the salt is hydrochloride.
24 . The method according to claim 16 , wherein the compound is a compound of Formula (III):
wherein
X is independently halo, alkyl, alkoxy or nitro;
m is 0, 1, 2, 3 or 4;
n is 1 or 2;
R 1 and R 2 are independently H— or alkyl; and
R 3 is H—, alkyl or aralkyl, and
wherein at least one of R 1 , R 2 and R 3 is not H—.
25 . The method according to claim 24 , wherein the compound is selected from the group consisting of:
2-amino-3-phenylpropyl (aminocarbonyl)methylcarbamate; 2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)methylcarbamate; 2-amino-3-phenylpropyl (aminocarbonyl)benzylcarbamate; 2-amino-3-phenylpropyl (aminocarbonyl)ethylcarbamate; 2-amino-3-(2-chlorophenyl)propyl (aminocarbonyl)methylcarbamate; 2-amino-3-(4-fluorophenyl)propyl (aminocarbonyl)methylcarbamate; 2-amino-3-(4-chlorophenyl)propyl (aminocarbonyl)methylcarbamate; 2-amino-3-(2,4-dichlorophenyl)propyl (aminocarbonyl)methylcarbamate; 2-amino-3-(3,4-dichlorophenyl)propyl (aminocarbonyl)methylcarbamate; 2-amino-3-(4-nitrophenyl)propyl (aminocarbonyl)methylcarbamate; 2-amino-3-(4-methylphenyl)propyl (aminocarbonyl)methylcarbamate; 2-amino-3-(4-ethoxyphenyl)propyl (aminocarbonyl)methylcarbamate; and 2-amino-4-phenylbutyl (aminocarbonyl)methylcarbamate.
26 . The method according to claim 25 , wherein the compound is selected from the group consisting of:
(2R)-2-amino-3-phenylpropyl (aminocarbonyl)methylcarbamate; (2R)-2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-phenylpropyl (aminocarbonyl)benzylcarbamate; (2R)-2-amino-3-phenylpropyl (aminocarbonyl)ethylcarbamate; (2R)-2-amino-3-(2-chlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-chlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(2,4-dichlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(3,4-dichlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2S)-2-amino-3-phenylpropyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-nitrophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-methylphenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-ethoxyphenyl)propyl (aminocarbonyl)methylcarbamate; and (2R)-2-amino-4-phenylbutyl (aminocarbonyl)methylcarbamate.
27 . The method according to claim 26 , wherein the salt is hydrochloride.
28 . A compound or hydrochloride salt thereof, wherein the compound is selected from the group consisting of:
(2R)-2-amino-3-phenylpropyl (aminocarbonyl)methylcarbamate; (2R)-2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-phenylpropyl (aminocarbonyl)benzylcarbamate; (2R)-2-amino-3-phenylpropyl (aminocarbonyl)ethylcarbamate; (2R)-2-amino-3-(2-chlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-chlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(2,4-dichlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(3,4-dichlorophenyl)propyl (aminocarbonyl)methylcarbamate; (2S)-2-amino-3-phenylpropyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-nitrophenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-methylphenyl)propyl (aminocarbonyl)methylcarbamate; (2R)-2-amino-3-(4-ethoxyphenyl)propyl (aminocarbonyl)methylcarbamate; and (2R)-2-amino-4-phenylbutyl (aminocarbonyl)methylcarbamate.Join the waitlist — get patent alerts
Track US2021113514A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.